Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (16)

2019

  1. CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC

    Cancer Research, Vol. 79, Núm. 17, pp. 4439-4452

2018

  1. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer

    FASEB Journal, Vol. 32, Núm. 12, pp. 7018-7027

2017

  1. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

    Journal of Thoracic Oncology, Vol. 12, Núm. 8, pp. 1268-1279

2016

  1. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer

    Cancer Discovery, Vol. 6, Núm. 9, pp. 1007-1021

2015

  1. Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition

    Cancer Research, Vol. 75, Núm. 20, pp. 4372-4383

2014

  1. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice

    Genes and Development, Vol. 28, Núm. 5, pp. 479-490

  2. Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

    Cancer Cell, Vol. 26, Núm. 6, pp. 909-922

2013

  1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Cancer Discovery, Vol. 3, Núm. 12, pp. 1355-1363

  2. Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6183-6192

  3. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer

    Clinical Cancer Research, Vol. 18, Núm. 18, pp. 4973-4985

  2. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 22, pp. 8699-8704

  3. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response

    Cancer Research, Vol. 72, Núm. 22, pp. 5921-5933

2010

  1. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

    Cancer Research, Vol. 70, Núm. 23, pp. 9827-9836

  2. Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors

    Cancer Cell, Vol. 17, Núm. 6, pp. 547-559

2009

  1. HIF2α cooperates with RAS to promote lung tumorigenesis in mice

    Journal of Clinical Investigation, Vol. 119, Núm. 8, pp. 2160-2170